Maik Pietzner

2 months ago | nature.com | Danielle Rasooly |Claudia Giambartolomei |Gina M. Peloso |Maik Pietzner |Eric Farber-Eger |Lawrence Phillips | +4 more

AbstractHeart failure (HF) has limited therapeutic options. In this study, we differentiated the pathophysiological underpinnings of the HF subtypes—HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF)—and uncovered subtype-specific therapeutic strategies. We investigated the causal roles of the human proteome and transcriptome using Mendelian randomization on more than 420,000 participants from the Million Veteran Program (27,799 HFrEF and 27,579 HFpEF cases).

Jan 9, 2025 | nature.com | Benjamin Wild |Maik Pietzner |Harry Hemingway |Claudia Langenberg

AbstractThe COVID-19 pandemic exposed a global deficiency of systematic, data-driven guidance to identify high-risk individuals. Here, we illustrate the utility of routinely recorded medical history to predict the risk for 1741 diseases across clinical specialties and support the rapid response to emerging health threats such as COVID-19. We developed a neural network to learn from health records of 502,489 UK Biobank participants.

May 19, 2024 | nature.com | Benjamin Wild |Maik Pietzner |Stefan Hegselmann |Harry Hemingway |Claudia Langenberg |Ulf Landmesser | +1 more

AbstractThe COVID-19 pandemic exposed a global deficiency of systematic, data-driven guidance to identify high-risk individuals. Here, we illustrate the utility of routinely recorded medical history to predict the risk for 1883 diseases across clinical specialties and support the rapid response to emerging health threats such as COVID-19. We developed a neural network to learn from health records of 502,460 UK Biobank.

Apr 28, 2024 | nature.com | Karl Smith-Byrne |Marios Dimitriou |Mine Koprulu |Maik Pietzner |Claudia Langenberg |Joshua Atkins | +10 more

AbstractCirculating proteins can reveal key pathways to cancer and identify therapeutic targets for cancer prevention. We investigate 2,074 circulating proteins and risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) using cis protein Mendelian randomisation and colocalization. We conduct additional analyses to identify adverse side-effects of altering risk proteins and map cancer risk proteins to drug targets.

Mar 29, 2023 | nature.com | Yu Xu |Scott Ritchie |Maik Pietzner |Loïc Lannelongue |Samuel A. Lambert |Sebastian May-Wilson | +17 more

AbstractThe use of omic modalities to dissect the molecular underpinnings of common diseases and traits is becoming increasingly common. But multi-omic traits can be genetically predicted, which enables highly cost-effective and powerful analyses for studies that do not have multi-omics1.